Nuvation Bio Inc.
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $31.70M | $-0.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | During market hours | $83.23M | $0.01 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | $15.70M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | During market hours | $13.12M | $-0.16 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.17 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | During market hours | $5.71M | $-0.15 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $727.00K | $-0.15 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | During market hours | – | – | – |
Press releases
Announcements Nuvation Bio filed with the SEC
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million
New financial obligation · Other events · EX-99.1 to Form 8-K
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
Nuvation Bio Announces Pricing of Upsized Offering of
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.2 to Form 8-K
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
DRIVEN BY SCIENCE FOCUSED ON LIFE
Material agreement · Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
DRIVEN BY SCIENCE FOCUSED ON LIFE
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
DRIVEN BY SCIENCE FOCUSED ON LIFE June
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
(Incorporated in the Cayman Islands with limited liability)
Other events · EX-99.1 to Form 8-K/A
(Incorporated in the Cayman Islands with limited liability)
Other events · EX-99.2 to Form 8-K/A
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Other events · EX-99.3 to Form 8-K/A
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
DRIVEN BY SCIENCE FOCUSED ON LIFE
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
DRIVEN BY SCIENCE FOCUSED ON LIFE
Regulation FD disclosure · EX-99.1 to Form 8-K
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Announces Discontinuation of NUV-422
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
DRIVEN BY SCIENCE FOCUSED ON LIFE
Regulation FD disclosure · EX-99.1 to Form 8-K
Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K